argenex SE $ARGX Shares Bought by Mirabella Financial Services LLP

Mirabella Financial Services LLP boosted its holdings in shares of argenex SE (NASDAQ:ARGX) by 144.5% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 2,976 shares of the company’s stock after buying an additional 1,759 shares during the quarter. Mirabella Financial Services LLP’s holdings in argenex were worth $2,191,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Capital World Investors increased its stake in shares of argenex by 0.4% in the third quarter. Capital World Investors now owns 1,959,504 shares of the company’s stock worth $1,445,113,000 after acquiring an additional 8,422 shares during the period. Wellington Management Group LLP lifted its position in argenex by 80.1% during the third quarter. Wellington Management Group LLP now owns 729,986 shares of the company’s stock valued at $538,408,000 after purchasing an additional 324,653 shares during the period. Bank of America Corp DE boosted its holdings in argenex by 1.9% in the third quarter. Bank of America Corp DE now owns 342,379 shares of the company’s stock valued at $252,525,000 after purchasing an additional 6,259 shares during the last quarter. Adage Capital Partners GP L.L.C. boosted its holdings in argenex by 114.3% in the second quarter. Adage Capital Partners GP L.L.C. now owns 297,113 shares of the company’s stock valued at $163,775,000 after purchasing an additional 158,476 shares during the last quarter. Finally, Two Sigma Investments LP grew its position in argenex by 570.3% during the 3rd quarter. Two Sigma Investments LP now owns 294,160 shares of the company’s stock worth $216,961,000 after purchasing an additional 250,278 shares during the period. 60.32% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities analysts have weighed in on ARGX shares. Truist Financial lifted their price objective on argenex from $950.00 to $1,030.00 and gave the company a “buy” rating in a research note on Thursday, January 8th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of argenex in a report on Wednesday, January 21st. Citizens Jmp lifted their price target on argenex from $925.00 to $944.00 and gave the company a “market outperform” rating in a research report on Friday, February 27th. JPMorgan Chase & Co. boosted their price target on argenex from $925.00 to $1,100.00 and gave the company an “overweight” rating in a report on Monday, December 8th. Finally, Wells Fargo & Company lowered their price objective on argenex from $1,317.00 to $1,247.00 and set an “overweight” rating on the stock in a research report on Friday, February 27th. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $999.22.

argenex Stock Down 3.0%

ARGX stock opened at $684.77 on Thursday. argenex SE has a 52-week low of $510.05 and a 52-week high of $934.62. The firm has a market cap of $42.37 billion, a P/E ratio of 35.08, a PEG ratio of 1.16 and a beta of 0.38. The company’s 50-day simple moving average is $797.33 and its 200-day simple moving average is $816.51.

argenex (NASDAQ:ARGX) last announced its quarterly earnings results on Thursday, February 26th. The company reported $8.02 earnings per share for the quarter, beating the consensus estimate of $6.05 by $1.97. The firm had revenue of $1.32 billion during the quarter, compared to analyst estimates of $1.30 billion. argenex had a return on equity of 38.51% and a net margin of 30.42%. On average, analysts anticipate that argenex SE will post 3.13 earnings per share for the current fiscal year.

About argenex

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.